The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

William D. Figg

PharmD.

National Cancer Institute

Medical Oncology

9000 Rockville Pike

USA

[email]@helix.nih.gov

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • PharmD., National Cancer Institute, Medical Oncology, 9000 Rockville Pike, USA. 2012
  • Clinical Pharmacology Program, National Cancer Institute, National Institutes of Health, Bethesda, USA. 1999 - 2010
  • Molecular Pharmacology Section, Medical Oncology Branch, Center for Cancer Research, Cancer Therapy and Evaluation Program, USA. 2001 - 2009
  • National Cancer Institute, Bethesda, Maryland, USA. 2008
  • Center for Cancer Research, National Cancer Institute, Warren Grant Magnuson Clinical Center, National Institutes of Health, USA. 2005

References

  1. Racial disparities in the association between variants on 8q24 and prostate cancer: a systematic review and meta-analysis. Troutman, S.M., Sissung, T.M., Cropp, C.D., Venzon, D.J., Spencer, S.D., Adesunloye, B.A., Huang, X., Karzai, F.H., Price, D.K., Figg, W.D. Oncologist (2012) [Pubmed]
  2. A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer. Figg, W.D., Woo, S., Zhu, W., Chen, X., Ajiboye, A.S., Steinberg, S.M., Price, D.K., Wright, J.J., Parnes, H.L., Arlen, P.M., Gulley, J.L., Dahut, W.L. J. Urol. (2010) [Pubmed]
  3. Disclosing a diagnosis of cancer: where and how does it occur? Figg, W.D., Smith, E.K., Price, D.K., English, B.C., Thurman, P.W., Steinberg, S.M., Emanuel, E. J. Clin. Oncol. (2010) [Pubmed]
  4. Current Status Of Thalidomide And CC-5013 In The Treatment Of Metastatic Prostate Cancer. Sissung, T.M., Thordardottir, S., Gardner, E.R., Figg, W.D. Anticancer. Agents. Med. Chem (2009) [Pubmed]
  5. Pharm. D. pathways to biomedical research: the National Institutes of Health special conference on pharmacy research. Figg, W.D., Chau, C.H., Okita, R., Preusch, P., Tracy, T.S., McLeod, H., Reed, M., Pieper, J., Knoell, D., Miller, K., Speedie, M., Blouin, R., Kroboth, P., Koda-Kimble, M.A., Taylor, P., Cohen, J., Giacomini, K. Pharmacotherapy (2008) [Pubmed]
  6. The Pharm.D. investigator in clinical pharmacology: supply and demand. Figg, W.D. Clin. Pharmacol. Ther. (2008) [Pubmed]
  7. Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer. Figg, W.D., Li, H., Sissung, T., Retter, A., Wu, S., Gulley, J.L., Arlen, P., Wright, J.J., Parnes, H., Fedenko, K., Latham, L., Steinberg, S.M., Jones, E., Chen, C., Dahut, W. BJU Int. (2007) [Pubmed]
  8. Heterogeneity in drug disposition determines interindividual variability of docetaxel pharmacokinetics. Figg, W.D., Chau, C.H. Cancer Biol. Ther. (2006) [Pubmed]
  9. The 2005 Leon I. Goldberg Young Investigator Award Lecture: Development of thalidomide as an angiogenesis inhibitor for the treatment of androgen-independent prostate cancer. Figg, W.D. Clin. Pharmacol. Ther. (2006) [Pubmed]
  10. Scientific collaboration results in higher citation rates of published articles. Figg, W.D., Dunn, L., Liewehr, D.J., Steinberg, S.M., Thurman, P.W., Barrett, J.C., Birkinshaw, J. Pharmacotherapy (2006) [Pubmed]
  11. Prostate cancer - 6th International Congress. Figg, W.D., Ockers, S. IDrugs (2006) [Pubmed]
  12. A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases. Figg, W.D., Liu, Y., Arlen, P., Gulley, J., Steinberg, S.M., Liewehr, D.J., Cox, M.C., Zhai, S., Cremers, S., Parr, A., Yang, X., Chen, C.C., Jones, E., Dahut, W.L. J. Urol. (2005) [Pubmed]
  13. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Figg, W.D., Dahut, W., Duray, P., Hamilton, M., Tompkins, A., Steinberg, S.M., Jones, E., Premkumar, A., Linehan, W.M., Floeter, M.K., Chen, C.C., Dixon, S., Kohler, D.R., Krüger, E.A., Gubish, E., Pluda, J.M., Reed, E. Clin. Cancer Res. (2001) [Pubmed]
  14. Pharmacokinetics of thalidomide in an elderly prostate cancer population. Figg, W.D., Raje, S., Bauer, K.S., Tompkins, A., Venzon, D., Bergan, R., Chen, A., Hamilton, M., Pluda, J., Reed, E. J. Pharm. Sci (1999) [Pubmed]
 
WikiGenes - Universities